Skip to content
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Home
(current)
Diseases
Parkinson's Disease
Multiple Sclerosis and Related Disorders
Headache
Amyotrophic Lateral Sclerosis
Epilepsy
Sleep Disorders
Stroke
Neuromuscular Disorders
Movement Disorders
View all Diseases
Topics
Biology
Diagnostics
Trial Updates
Treatment
Prevention
Surgery
Imaging
Genetics
COVID-19
View all Topics
Conferences
CONy 2023
ACTRIMS 2023
ISC 2023
EHC 2022
AES 2022
WSC 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Anibal Chertcoff
1:14
EBV & MS risk at ACTRIMS
Anibal Chertcoff
• 27 Feb 2023
3:41
Phenotyping the prodrome could lead to earlier recognition of MS
Anibal Chertcoff
• 27 Feb 2023
4:55
The burden of psychiatric morbidity in the MS prodrome
Anibal Chertcoff
• 27 Feb 2023
1:45
Future research options in polypharmacy associated with multiple sclerosis
Anibal Chertcoff
• 28 Oct 2022
2:07
Impacts of polypharmacy on MS patients’ outcomes
Anibal Chertcoff
• 28 Oct 2022
6:12
Population-based study on polypharmacy and multiple sclerosis
Anibal Chertcoff
• 28 Oct 2022
2:36
Strategies to reduce polypharmacy in multiple sclerosis
Anibal Chertcoff
• 28 Oct 2022